ClinicalTrials.gg
RecruitingNCT07553429Updated Nov 13, 2026

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

A Phase 1/2 interventional study of Low dose BI 3812465 and Medium dose BI 3812465 in Diabetic Macular Edema, sponsored by Boehringer Ingelheim. Recruiting at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 13, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
117th of 244
49 · median 45
Started
2026
with 9 others
Phase 1/2
31 of 276
3 open now
Primary completion
2027-03
later than 17 of 32 live
Registered
273rd of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 117th largest by planned enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2026, is one of 31 in phase 1/2, reaches primary completion later than 17 of the 32 other live ones, and was the 273rd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this condition. This is the first time BI 3812465 is given to humans.

This study has 2 parts. In Part 1, a small number of participants receive low, medium, or high doses of BI 3812465. The first participants to start the study get low doses of BI 3812465. Participants who start later get higher doses only if the lower doses were tolerated. In Part 2, a larger number of participants are placed into low, medium, or high dose groups. Participants in both parts of the study get BI 3812465 as injections into the back of the eye for a total of 3 eye injections.

Participants are in the study for up to 7 months. During this time, they visit the study site 19 times. Where possible, some visits can be done at the participant's home instead of the study site. At study visits, the doctors check the severity of participants' eye condition and note any health problems that could have been caused by BI 3812465.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants, study eye:

  • Center-involved diabetic macular edema (CI-DME) defined as CST ≥320 μm (micrometers) at Screening, as confirmed on spectral-domain optical coherence tomography (SD-OCT) and confirmed by the central reading center (CRC).
  • Sufficiently clear ocular media, adequate pupillary dilation, and fixation, to permit quality fundus imaging.

All participants:

  • Diagnosis of diabetes mellitus (DM) type 1 or type 2 under regular treatment, with HbA1c \<12%.
  • Be willing and able to understand the study procedures and the risks involved.
  • Signed and dated written in accordance with international council for harmonization - good clinical practices (ICH-GCP) and local legislation prior to admission to the trial and any trial related procedures.
  • Age ≥18 years (or above legal age according to local legislation) at time of signing the informed consent form (ICF).
  • Male or female participants

    • Woman of (WOCBP) must be ready and able to use highly effective methods of
    • For men, contraception (condom or complete abstinence) should be used as precaution to prevent pregnancy of a partner and/or exposure of an existing embryo or fetus.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

All participants, study eye:

  • Only one functional eye, even if that eye was otherwise eligible for the study. Fellow eye must have sufficient visual function per the investigator's medical judgment in consultation with the participant, to support the participant's daily functioning.
  • Evidence of active proliferative diabetic retinopathy (PDR).
  • Evidence of active retinal neovascularization (NV) clinical exam and/or Ultra-Widefield Color Fundus Photography ((UWF-)CFP) within the early treatment diabetic retinopathy study (ETDRS) 7-field, confirmed by the CRC grading. Potential participants with NV outside of the ETDRS 7-field on ultra-widefield imaging may be included in the trial if this condition, based on the assessment of the investigator, does not require acute treatment.
  • Evidence of active NV of the iris (small iris tufts are not an exclusion) or in the anterior chamber angle.
  • Additional eye disease in the study eye that could compromise trial participation:

    • Uncontrolled glaucoma or intraocular pressure (IOP) >24 mmHg despite treatment
    • History of high myopia >8 diopters in the study eye
    • Anterior segment and vitreous abnormalities in the study eye that would preclude adequate detection of intraocular inflammation (IOI) or other pathologies
    • Ocular conditions which, at discretion of the investigator, might interfere with the outcome of the trial.
  • Previously received ocular gene therapy or cell therapy.
  • use locally or systemically within 1 month prior to Screening.
  • Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser capsulotomy may be permitted, if performed more than 2 months prior to Day 1.

Further exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Part 1: Treatment arm A

    Low dose of BI 3812465.

    Biological: Low dose BI 3812465

  • Experimental
    Part 1: Treatment arm B

    Medium dose of BI 3812465.

    Biological: Medium dose BI 3812465

  • Experimental
    Part 1: Treatment arm C

    High dose BI 3812465.

    Biological: High dose BI 3812465

  • Experimental
    Part 2: Treatment arm A

    Low dose BI 3812465.

    Biological: Low dose BI 3812465

  • Experimental
    Part 2: Treatment arm B

    Medium dose BI 3812465.

    Biological: Medium dose BI 3812465

  • Experimental
    Part 2: Treatment arm C

    High dose BI 3812465.

    Biological: High dose BI 3812465

Interventions

  • BiologicalLow dose BI 3812465

    BI 3812465

  • BiologicalMedium dose BI 3812465

    BI 3812465

  • BiologicalHigh dose BI 3812465

    BI 3812465

06

What researchers measure

Primary outcomes

  1. Part 1: Occurrence of dose limiting events (DLEs) from first investigational medicine product (IMP) administration until end of study (EOS)

    Time frame: Up to 169 days.

  2. Part 2: Occurrence of ocular adverse events (AEs) in the study eye from first IMP administration until EOS

    Time frame: Up to 169 days.

Secondary outcomes

  1. Occurrence of AEs from first IMP administration until EOS

    Time frame: Up to 169 days.

  2. Occurrence of serious adverse events (SAEs) from first IMP administration until EOS

    Time frame: Up to 169 days.

  3. Part 1: Occurrence of ocular AEs in the study eye from first IMP administration until EOS

    Time frame: Up to 169 days.

07

Study locations

28 of 29 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 16 phase 1/2 interventional studies under Macular Edema, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 68. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 28, 2026
StartActual
May 14, 2026
Primary completionEst.
Mar 23, 2027
CompletionEst.
Jul 6, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Retina Consultants of Texas-Bellaire-67493 · Bellaire, United StatesNot yet recruiting→Recruiting
  • Associated Retina Consultants, Ltd. · Phoenix, United StatesNot yet recruiting→Recruiting
  • Retina Consultants of Texas · San Antonio, United StatesNot yet recruiting→Recruiting
  • Retina Associates of Southern California · Huntington Beach, United StatesNot yet recruiting→Recruiting
  • Retina Consultants of Texas-The Woodlands-67575 · The Woodlands, United StatesNot yet recruiting→Recruiting
Show site
  • Retina Consultants of Texas · San Antonio, United States
Show 1 removed
  • Retina Consultants of Texas - San Antonio Medical Center · San Antonio, United States
across 3 updates, Sep 30, 2026 – Nov 13, 2026
Show all 3 updates
  1. Nov 13, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Retina Associates of Southern California · Huntington Beach, United StatesNot yet recruiting→Recruiting
    • Retina Consultants of Texas-The Woodlands-67575 · The Woodlands, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 14, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Associated Retina Consultants, Ltd. · Phoenix, United StatesNot yet recruiting→Recruiting
    • Retina Consultants of Texas · San Antonio, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date
  3. Sep 30, 2026
    1 site added, 1 site removed. Retina Consultants of Texas-Bellaire-67493 is now Recruiting
    Show site
    • Retina Consultants of Texas · San Antonio, United States
    Show 1 removed
    • Retina Consultants of Texas - San Antonio Medical Center · San Antonio, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553429
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
May 14, 2026
Primary completion
Mar 23, 2027 (estimated)
Completion
Jul 6, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion